Kerry Bozza Funkhouser at BIC 2025 Roundtable on Heavy Menstrual Bleeding and Rare Bleeding Disorders
Kerry Bozza Funkhouser, the Executive Director for the Foundation for Women & Girls with Blood Disorders, has shared a post on LinkedIn:
“Thrilled to share I’ll be joining Dr. Amy Shapiro, Dr. Giancarlo Castaman, and Dr. Anna Maria Fulghesu on September 11, preceding the 13th BIC International Conference (Sept 12–14 in Padua, Italy) for a roundtable discussion on heavy menstrual bleeding (HMB) in adolescents and rare bleeding disorders. HMB is common, but when it hides an underlying bleeding disorder, early recognition is critical.
This session will bring together multiple specialties and education/advocacy voices to explore best practices for timely diagnosis and effective management. Many thanks to Hemorare for the invitation to contribute to this important dialogue.”
You can learn more about the program here.
Discover more on Hemostasis Today.
-
Sep 9, 2025, 05:53Noel Hiney Highlights the Value of Blood Donation and Community Support
-
Sep 8, 2025, 22:5650% of DOAC Doses are Inappropriate in Older Adults? On The Role of Appropriate Dosing
-
Sep 8, 2025, 07:48Andreas Zirlik Announces EAS Rare Lipid Disorders Course at 7th Cardio Summit Graz
-
Sep 8, 2025, 07:11Naveen Pemmaraju at SOHO 2025: Presenting Effects of Rusfertide for Polycythemia Vera on Behalf of VERIFY Colleagues
-
Sep 8, 2025, 06:54Indraneel Deshmukh Presenting Posters on Polycytemia Vera and More at SOHO 2025
-
Sep 10, 2025, 03:36International Journal of Stroke: Rising Incidence of Stroke in Young Adults
-
Sep 8, 2025, 14:22GLP-1 Receptor Agonists and Cardiovascular Benefits․ Role of Clinical Features
-
Sep 8, 2025, 14:21Hamza A. Salim: CTA Collateral Impairment Score Enhances Stroke Prognosis Accuracy
-
Sep 8, 2025, 06:19Maria Abbattista: From Combined Hormonal Contraceptives to Cerebral Vein Thrombosis
-
Sep 8, 2025, 06:12David Smadja: Molecular Determinants of Thrombosis Recurrence Risk Across Venous Thromboembolism Subtypes
-
Sep 8, 2025, 14:24Von Willebrand Factor as a Therapeutic Target․ From Development to Clinical Application
-
Sep 8, 2025, 02:35Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
-
Sep 7, 2025, 14:16Mary Kiige: Biological Hemoglobin Oxygen Carrier as a Lifesaving Oxygen Bridge
-
Sep 7, 2025, 14:13Breakthrough in Blood: Cécile Denis and INSERM Team Develop Nanobody Therapy for Type 1 VWD
-
Sep 2, 2025, 13:53Cost-Effective Strategies to Reduce Anaemia Highlighted in The Lancet Haematology
-
Sep 9, 2025, 04:57World Thrombosis Day 2025: Louise Bannon Invites Donations and Partnerships
-
Sep 8, 2025, 15:10Michael Makris on WHO’s Essential Medicines List Update: A Win for the Global Haemophilia Community
-
Sep 8, 2025, 14:26European Haemophilia Consortium Marks World PT Day: Physiotherapy Empowers People with Bleeding Disorders
-
Sep 8, 2025, 07:03Omar Adwan Explains the Key Difference Between Serum and Plasma
-
Sep 8, 2025, 07:00French Reference Center for Hemophilia Presented at The 22nd Turkish Hemophilia Congress